logo-loader
viewFresenius Medical Care

Akorn shares slip after court rules that Fresenius can cancel its buyout of the generic drugmaker

Fresenius scrapped the merger after an investigation found Akorn had a history of fraudulent product data submissions

Scales of justice statue
The Delaware Supreme Court upheld a previous ruling in favor of Fresenius

Shares of Akorn Inc (NASDAQ:AKRX) slipped double digits after a judge ruled that German health care company Fresenius Medical Care (NYSE:FMS) had sufficient cause to end its $4.8 billion bid for the company.

Akorn shares plummeted about 28% to $4.05 in Monday afternoon trading while Fresenius shares were down nearly 9% to $35.73.

READ: Akorn's stock soars after FDA approves ANDA for eyelash treatment Bimatoprost

After the ink on the agreement had dried, an independent investigation revealed that generic drugmaker Akorn had a history of fraudulent product data submissions.

Fresenius, a provider of kidney dialysis care, sought to end the agreement.

Judge Travis Laster found in October that the termination of the merger was valid, citing Akorn’s compliance issues.

The judge also found that Akorn had failed to continue operating as normal after inking the deal.

Laster wrote that Akorn's "magnitude of inaccuracies would reasonably be expected to result in a material adverse effect," as per a Reuters report.

Akorn stood its ground and appealed the decision, claiming that it was a breach of a binding merger agreement and that Fresenius was suffering from buyer’s remorse.

The Delaware Supreme Court was not swayed, issuing an order that upheld Judge Laster’s findings, as per a Bloomberg report.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

 

 

Quick facts: Fresenius Medical Care

Price: 36.54 USD

NYSE:FMS
Market: NYSE
Market Cap: $21.94 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Matinas BioPharma welcomes two 'huge' catalysts for the...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Chief Medical Officer Dr Terry Ferguson tells Proactive two 'huge' catalysts for the omega-3 class transpired last week. Dr Ferguson explains how Amarin Corporation's (NASDAQ:AMRN) meetings with an FDA advisory committee and with the American...

1 hour, 16 minutes ago

2 min read